๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 17 Foshan 5 Dongguan 2 Beijing 2 Nanning 2
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou17 Foshan5 Dongguan2 Beijing2 Nanning2
All 20 locations
Target enrolment
to

Trials with a site in Guangzhou

17 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
NCT07750704ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
153
Guangzhou
2026-09
Recruiting
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
NCT07696832Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
Guangdong Association of Clinical Trials
Observational
265
Guangzhou
2026-01-20
Recruiting
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
NCT07375316Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
Guangdong Association of Clinical Trials
Phase 2
115
Guangzhou, Chengdu
2025-11-05
Recruiting
IBI351 Plus Cetuximab ฮฒ in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07198841Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
Recruiting
RGL-270 + ICI in Advanced NSCLC
NCT07652125NSCLC
Guangdong Association of Clinical Trials
Not applicable
40
Guangzhou
2025-10-25
Not yet open
A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
NCT07198620Lung Cancer (NSCLC)
Guangdong Association of Clinical Trials
Observational
600
Guangzhou
2025-10-01
Not yet open
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Active, closed
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Guangdong Association of Clinical Trials
Phase 4
41
Dongguan, Foshan, Guangzhou
2024-08-01
Recruiting
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
NCT06092086ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
126
Guangzhou
2023-08-18
Active, closed
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
NCT05957510Small-cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
66
Guangzhou
2023-07-07
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505MRD
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Recruiting
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
NCT05457049Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Active, closed
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)
NCT04841811Lung Cancer
Guangdong Association of Clinical Trials
Phase 3
192
Guangzhou
2022-06-20
Active, closed
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
NCT04015778Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
316
Guangzhou
2019-08-08
Recruiting
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
NCT04286841Immunotherapy, Lung Cancer
Guangdong Association of Clinical Trials
Observational
100
Guangzhou
2019-05-01
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

10 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 17 studies
PhaseStudiesRecruitingShare
Phase 29652.9%
Observational4323.5%
Not applicable2111.8%
Phase 3105.9%
Phase 4105.9%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Guangdong Association of Clinical Trials1710
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.